Fenbendazole and Cancer: What the Evidence Actually Shows

Evidence review · Last updated November 6, 2026

Fenbendazole is a benzimidazole anthelmintic — a dewormer approved for dogs, cats, horses, and livestock. Since 2019, it has also been one of the most discussed “repurposed drug” candidates in cancer forums, after Joe Tippens attributed his recovery from small cell lung cancer to a regimen built around it. This article reviews what science actually knows, layer by layer, from the least to the most reliable form of evidence.

Why evidence layers matter

Medical evidence comes in a hierarchy. Cell-culture results are the weakest tier: they show biological activity, not clinical benefit. Animal studies are stronger but frequently fail in translation. Case reports describe outcomes in one or a few patients and cannot separate a drug’s effect from concurrent treatment, natural disease variation, or chance. Only controlled clinical trials in humans can establish that a treatment works. Keeping these layers distinct is the core discipline of this entire topic.

Layer 1: Laboratory studies

The study most often cited in fenbendazole discussions was published in Scientific Reports in 2018. Researchers found that fenbendazole acts as a moderate microtubule-destabilizing agent in human cancer cells, disrupts glucose uptake by down-regulating GLUT transporters and hexokinase II, promotes mitochondrial p53 translocation, and blocked tumor growth in mice when fed orally (Dogra et al., 2018 — full citation in Sources).

Those are real findings, published by legitimate researchers. What they do not say is equally important: they do not demonstrate that the drug shrinks human tumors at doses a person could safely take. Drug development is littered with compounds that looked powerful in a dish and failed in patients. The authors themselves framed fenbendazole as a compound that “may be evaluated as a potential therapeutic agent” — a call for research, not a result.

Layer 2: Animal studies

The 2018 work included a xenograft mouse experiment in which oral fenbendazole slowed tumor growth. Additional preclinical studies in other cancer models have appeared since, and a 2024 review in Anticancer Research collated the preclinical and case-report literature. Two cautions apply. First, mouse tumor models predict human outcomes only unreliably — a majority of agents active in mouse models do not succeed clinically. Second, laboratory studies use controlled doses and monitoring; none of that infrastructure transfers to self-treatment at home.

Layer 3: Case reports and case series

A handful of peer-reviewed case publications describe cancer patients who took fenbendazole on their own initiative:

• A 2021 case series in Clinical Oncology Case Reports (Chiang et al., Stanford-affiliated authors) described patients with progressive disease who self-administered fenbendazole alongside other therapy and showed imaging responses.
• A 2025 case series of self-administration in three patients added similar anecdotes with imaging documentation.
• Joe Tippens’s own account, published on his personal website, remains the most famous single anecdote.

These reports deserve careful reading rather than dismissal. But they share structural limitations: tiny numbers, no control group, selection by outcome (we hear about survivors), and — critically — concurrent treatment. In nearly every published case, the patient was also receiving conventional therapy. When a tumor regresses after two overlapping interventions, neither patient nor reader can attribute the response to the non-standard one. This is why case reports generate hypotheses; they cannot test them.

Layer 4: Clinical trials — where the story has not caught up

As of our last review of ClinicalTrials.gov, no completed controlled trial has tested fenbendazole as a cancer treatment in humans. This absence is decisive for how the anecdotes should be interpreted. It is not because pharmaceutical companies are uninterested in cheap drugs — repurposing is an active, published research strategy — but because nothing has produced a completed, reported human trial here.

Context helps: cousin drugs in the same benzimidazole family have reached human trials. Mebendazole has been studied in recurrent high-grade glioma (a registered phase trial exists), with results that have not produced an approved indication. That contrast shows what the real evidence path looks like — and that fenbendazole has not traveled it.

In May 2026, the American Society of Clinical Oncology published a clinical notice recommending that ivermectin and fenbendazole should not be used for the treatment of cancer, nor as an adjunct to standard therapy, outside of clinical trials, citing the lack of established benefit and potential for toxicity and interactions. The American Cancer Society’s patient-facing explainer states plainly that the drug has not been tested in humans as a cancer treatment.

The confounder problem, stated plainly

The viral story rests on one visible fact: a man with terminal disease got better, and he was taking the drug. What the popular version omits: he had also received standard chemoradiation, and public accounts — including a peer-reviewed 2022 commentary analyzing how his story spread — note he participated in an immunotherapy (pembrolizumab) clinical trial. Small cell lung cancer can also respond dramatically to treatment on its own natural course. With multiple overlapping causes and a sample size of one, attribution is not just difficult; it is impossible. Our documented timeline lays out each event with sources.

What this means if you are a patient

“No completed trials” does not mean “proven useless” — it means nobody knows, and the honest state of knowledge is uncertainty. But the burden of proof for adding any drug to cancer treatment is high, because treatments can harm as well as help, and because proven therapy delayed can be survival lost. If the topic interests you, bring it to your oncologist; our guide to evaluating treatment claims includes a question list built for exactly that conversation. And read the other side of the ledger: what is documented about harms.

Sources